Table 1.

Baseline patient characteristics

Variable	N (%*) or median (range)
Total	30 (100)
Age, y	33 (20-69)
Sex
Male	16 (53)
Female	14 (47)
Frontline therapy
A(B)VD†	24 (80)
BV-A(B)VD	1 (3)
ABVE-PC	1 (3)
BEACOPP‡	2 (7)
RCHOP/REPOCH	2 (7)
Prior brentuximab exposure	6 (20)
Prior nivolumab or pembrolizumab exposure	6 (20)
Prior radiotherapy	7 (23)
Conditioning regimen
BEAM	30 (100)
Risk factors
Primary refractory disease	17 (57)
Relapse within 12 mo	5 (17)
Extranodal disease at relapse	8 (27)
At least 1 of above 3 factors	26 (87)
Residual disease after salvage	3 (10)
B symptoms at relapse	2 (7)
>1 salvage therapy	5 (17)
At least 1 of above 6 factors	27 (90)
At least 2 of above 6 factors	12 (40)
Disease status at study entry (post-ASCT)
Partial remission	2 (7)
Complete remission	28 (93)

A(B)VD, doxorubicin, bleomycin, vinblastine, and dacarbazine; ABVE-PC, doxorubicin, bleomycin, vincristine, etoposide, prednisone, cyclophosphamide; BEACOPP, bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone; BEAM, carmustine, etoposide, cytarabine, and melphalan; BV, brentuximab vedotin; RCHOP, rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone; REPOCH, rituximab plus etoposide, prednisone, vincristine, cyclophosphamide, and doxorubicin.

^*Percentages may not add to 100 because of rounding.

^†With rituximab in 1 patient.

^‡Given after ABVD in 1 additional patient.